These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 19289118)
1. A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference. Lombardi MS; Jaspers L; Spronkmans C; Gellera C; Taroni F; Di Maria E; Donato SD; Kaemmerer WF Exp Neurol; 2009 Jun; 217(2):312-9. PubMed ID: 19289118 [TBL] [Abstract][Full Text] [Related]
2. Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts. van Bilsen PH; Jaspers L; Lombardi MS; Odekerken JC; Burright EN; Kaemmerer WF Hum Gene Ther; 2008 Jul; 19(7):710-9. PubMed ID: 18549309 [TBL] [Abstract][Full Text] [Related]
3. Toward therapy for DYT1 dystonia: allele-specific silencing of mutant TorsinA. Gonzalez-Alegre P; Miller VM; Davidson BL; Paulson HL Ann Neurol; 2003 Jun; 53(6):781-7. PubMed ID: 12783425 [TBL] [Abstract][Full Text] [Related]
4. Allele-specific cancer cell killing in vitro and in vivo targeting a single-nucleotide polymorphism in POLR2A. Mook OR; Baas F; de Wissel MB; Fluiter K Cancer Gene Ther; 2009 Jun; 16(6):532-8. PubMed ID: 19165236 [TBL] [Abstract][Full Text] [Related]
5. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Pfister EL; Kennington L; Straubhaar J; Wagh S; Liu W; DiFiglia M; Landwehrmeyer B; Vonsattel JP; Zamore PD; Aronin N Curr Biol; 2009 May; 19(9):774-8. PubMed ID: 19361997 [TBL] [Abstract][Full Text] [Related]
6. Allele-Selective Suppression of Mutant Huntingtin in Primary Human Blood Cells. Miller JRC; Pfister EL; Liu W; Andre R; Träger U; Kennington LA; Lo K; Dijkstra S; Macdonald D; Ostroff G; Aronin N; Tabrizi SJ Sci Rep; 2017 Apr; 7():46740. PubMed ID: 28436437 [TBL] [Abstract][Full Text] [Related]
7. Allele-specific silencing by RNA interference. Hohjoh H Methods Mol Biol; 2010; 623():67-79. PubMed ID: 20217544 [TBL] [Abstract][Full Text] [Related]
8. HD phenocopies--possible role of Saitohin gene. Janković N; Kecmanović M; Dimitrijević R; Keckarević Marković M; Dobricić V; Keckarević D; Savić Pavicević D; Romac S Int J Neurosci; 2008 Mar; 118(3):391-7. PubMed ID: 18300012 [TBL] [Abstract][Full Text] [Related]
9. Modulation of age at onset of Huntington disease patients by variations in TP53 and human caspase activated DNase (hCAD) genes. Chattopadhyay B; Baksi K; Mukhopadhyay S; Bhattacharyya NP Neurosci Lett; 2005 Feb; 374(2):81-6. PubMed ID: 15644269 [TBL] [Abstract][Full Text] [Related]
10. Huntingtin Haplotypes Provide Prioritized Target Panels for Allele-specific Silencing in Huntington Disease Patients of European Ancestry. Kay C; Collins JA; Skotte NH; Southwell AL; Warby SC; Caron NS; Doty CN; Nguyen B; Griguoli A; Ross CJ; Squitieri F; Hayden MR Mol Ther; 2015 Nov; 23(11):1759-1771. PubMed ID: 26201449 [TBL] [Abstract][Full Text] [Related]
11. Allele-specific silencing of mutant huntingtin in rodent brain and human stem cells. Drouet V; Ruiz M; Zala D; Feyeux M; Auregan G; Cambon K; Troquier L; Carpentier J; Aubert S; Merienne N; Bourgois-Rocha F; Hassig R; Rey M; Dufour N; Saudou F; Perrier AL; Hantraye P; Déglon N PLoS One; 2014; 9(6):e99341. PubMed ID: 24926995 [TBL] [Abstract][Full Text] [Related]
12. Lentivirus-mediated small interfering RNA targeting VEGF-C inhibited tumor lymphangiogenesis and growth in breast carcinoma. Guo B; Zhang Y; Luo G; Li L; Zhang J Anat Rec (Hoboken); 2009 May; 292(5):633-9. PubMed ID: 19382240 [TBL] [Abstract][Full Text] [Related]
13. Genetic background of Huntington disease in Croatia: Molecular analysis of CAG, CCG, and Delta2642 (E2642del) polymorphisms. Hećimović S; Klepac N; Vlasić J; Vojta A; Janko D; Skarpa-Prpić I; Canki-Klain N; Marković D; Bozikov J; Relja M; Pavelić K Hum Mutat; 2002 Sep; 20(3):233. PubMed ID: 12204002 [TBL] [Abstract][Full Text] [Related]
14. A Comprehensive Haplotype-Targeting Strategy for Allele-Specific HTT Suppression in Huntington Disease. Kay C; Collins JA; Caron NS; Agostinho LA; Findlay-Black H; Casal L; Sumathipala D; Dissanayake VHW; Cornejo-Olivas M; Baine F; Krause A; Greenberg JL; Paiva CLA; Squitieri F; Hayden MR Am J Hum Genet; 2019 Dec; 105(6):1112-1125. PubMed ID: 31708117 [TBL] [Abstract][Full Text] [Related]
15. Mitochondrial DNA haplogroups do not influence the Huntington's disease phenotype. Mancuso M; Kiferle L; Petrozzi L; Nesti C; Rocchi A; Ceravolo R; Orsucci D; Maluccio MR; Bonuccelli U; Filosto M; Siciliano G; Murri L Neurosci Lett; 2008 Oct; 444(1):83-6. PubMed ID: 18706972 [TBL] [Abstract][Full Text] [Related]
16. Allele-Specific Knockdown of Mutant Huntingtin Protein via Editing at Coding Region Single Nucleotide Polymorphism Heterozygosities. Oikemus SR; Pfister EL; Sapp E; Chase KO; Kennington LA; Hudgens E; Miller R; Zhu LJ; Chaudhary A; Mick EO; Sena-Esteves M; Wolfe SA; DiFiglia M; Aronin N; Brodsky MH Hum Gene Ther; 2022 Jan; 33(1-2):25-36. PubMed ID: 34376056 [TBL] [Abstract][Full Text] [Related]
17. Huntington's disease: neurological assessment of potential gene carriers presenting for predictive DNA testing. McCusker E; Richards F; Sillence D; Wilson M; Trent RJ J Clin Neurosci; 2000 Jan; 7(1):38-41. PubMed ID: 10847649 [TBL] [Abstract][Full Text] [Related]